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Background: The objective of phase II cancer clinical trials is to determine if a treatment has sufficient activity to
warrant further study. The efficiency of a conventional phase II trial design has been the object of considerable
debate, particularly when the study regimen is characteristically cytostatic. At the time of development of a phase II
cancer trial, we accumulated clinical experience regarding the time to progression (TTP) for similar classes of drugs
and for standard therapy. By considering the time to event (TTE) in addition to the tumor response endpoint, a
mixed-endpoint phase II design may increase the efficiency and ability of selecting promising cytotoxic and
cytostatic agents for further development.
Methods: We proposed a single-arm phase II trial design by extending the Zee multinomial method to fully use
mixed endpoints with tumor response and the TTE. In this design, the dependence between the probability of
response and the TTE outcome is modeled through a Gaussian copula.
Results: Given the type I and type II errors and the hypothesis as defined by the response rate (RR) and median
TTE, such as median TTP, the decision rules for a two-stage phase II trial design can be generated. We demonstrated
through simulation that the proposed design has a smaller expected sample size and higher early stopping
probability under the null hypothesis than designs based on a single-response endpoint or a single TTE endpoint.
Conclusions: The proposed design is more efficient for screening new cytotoxic or cytostatic agents and less likely
to miss an effective agent than the alternative single-arm design.
Keywords: Phase II trial design, Multiple-endpoints, Cytostatic drug testing, Target therapyBackground
The primary objective of phase II trials in oncology is to
identify the agents or treatments that are sufficiently ef-
ficacious in antitumor activity to warrant further investi-
gation in phase III trials. The tumor response rate (RR)
is a common primary endpoint used to indicate possible
antitumor activity for a study treatment in phase II can-
cer clinical trials [1]. However, studies of a few novel
agents in recent years have revealed that other end-
points, such as the time to progression (TTP) or
progression-free survival (PFS), are also relevant in
assessing the antitumor activity of various new agents
[2–5]; this is because several of the studied agents have* Correspondence: bzee@cuhk.edu.hk
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proving tumor RR [6, 7]. For example, despite a low
tumor RR [8], agents such as sorafenib in renal cell car-
cinoma have been observed to have significant PFS and
overall survival benefits [6]. Therefore, relying on a sin-
gle traditional RR can lead to an unexpectedly high type
II error, meaning that promising drugs are likely to be
missed because of a lack of observed activity.
Phase II trials can also be used to rapidly terminate
inefficacious drugs that do not warrant further develop-
ment. The multistage design, which is typically a two-
stage design, was developed to screen out inactive drugs
at the interim stages. One of the advantages of this
method is that it enables early termination of a futile
study and consequently patient resources can be con-
served for other studies. Fleming [9] and Simon [10]
proposed multistage designs where tumor RR is the only
endpoint in assessing antitumor activity for drugs.rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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points have received considerable attention in the past
decade [11–13], using the time-to-event (TTE) end-
point alone requires a longer period for assessing the
outcome, which may not be an ideal screening tool for
selecting active drugs and terminating inactive drugs
[14]. In some clinical trials, a new therapeutic agent at
the time of phase II development might have uncertain
levels of drug activity, regardless of the extent to which
it has been studied, and whether the TTE endpoint
alone is the optimal choice is unclear. Therefore, com-
bining both the response endpoint and the TTE end-
point for assessing new agents is a logical option. For
example, in a Phase II study of antisense AEG35156 in
combination with sorafenib for advanced hepatocellular
carcinoma (HCC), the original design was to use TTP
alone as primary endpoint because the drug activity of
this antisense was expected to improve TTP more so
than tumor RR. However, the benefits based on TTP
were not obvious enough to show drug activity but
tumor RR did. The results have shown that the median
TTP was 4.0 months and 2.6 months for the study
treatment and control arms, respectively. The primary
TTP was in favor of the study treatment but did not
reach statistical significance since the sample size was
designed to be small in this Phase II study. It was fur-
ther pointed out that patients who had dose modifica-
tions according to protocol did significantly better in
TTP than those who had no dose reduction, possibly
due to potential side effects. The response status as an
outcome showing short term drug activity may also
contribute, and in this example we have observed a
clear treatment activity in the study treatment and no
activity in the control (5 versus 0 responses). If we had
used a mixed endpoints design in the first place, we
would have shown the drug was active in this study
[15].
Zee et al. [16] and Sun et al. [17] proposed a multi-
nomial design to accommodate both tumor response
and progressive disease in evaluating the effectiveness of
a study agent, in which the early progressive disease
(EPD) rate was incorporated into the composite hypoth-
esis setting. The additional information from the EPD
endpoint enabled the multinomial design to provide a
better decision rule than those based on the response
endpoint alone, with a higher probability of early stop-
ping and smaller expected sample size [18]. However,
the lack of concordance between binary EPD at a fixed
time point in phase II trials and TTE endpoints such as
TTP, PFS, and overall survival (OS) in subsequent phase
III studies suggests that EPD may not be the most ap-
propriate endpoint for developing a multistage phase II
design [5]. The discrete characteristic of the EPD end-
point may lose crucial information because of itsarbitrary definition in the choice of a fixed time point in
the evaluation [19].
In this study, we considered using the tumor RR and a
TTE endpoint such as TTP or PFS, instead of the di-
chotomized EPD variable, for developing a stopping rule
for multistage single-arm phase II trials. Because of the
association between TTE and RR endpoints within the
same patient, and because ignoring such an association
can lead to higher type I or type II errors, we adopted
the Gaussian copula method to model the dependence
structure between a binary RR endpoint and a continu-
ous TTE endpoint. If the tumor response probability is
determined by a normal variable through the probit
model and the underlying TTE is assumed to follow an
exponential distribution, then the dependence between
RR and TTE is expressed as a correlation between the
underlying normal variable and the exponential variable.
Under these conditions, our design allows early rejection
of drugs if they have an unacceptably low RR after stage
I and a short median TTE. The Methods section de-
scribes the multistage hypothesis-testing procedure
based on the copula model. The Results section reports
a simulation study conducted to assess the performance
of the proposed design under various correlation
settings.
Methods
In our phase II clinical trial design with tumor response
and TTE endpoints, the null hypothesis and the alterna-
tive hypothesis are expressed as





: p > p1 or T

med > T 1
  ð1Þ
where Tmed
* is the true median TTE T* that is assumed
to follow exponential distribution with hazard rate λ and
hence Tmed
* = ln 2/λ. Expecting that a correlation be-
tween tumor response endpoint and TTE endpoint ex-
ists is logical because a high RR is typically related to a
long TTE, particularly in studies with cytotoxic agents
[20]. Therefore, in this design, the dependence between
the probability of response and the hazard rate function
for the TTE endpoint is modeled using a Gaussian cop-
ula (Appendix section A). We further assumed that the
censoring time Ti
C is noninformative (i.e., the marginal
density function of tumor response and the true TTE
and the dependence structure are not affected by censor-
ing once the copula is prespecified in the design). In
practice, the censoring observations in most trials affect
the true median TTE. Therefore, for the null hypothesis
that experimental treatment is inactive, the decision to
reject the null hypothesis can be made based on the
Kaplan–Meier median Tmed derived from the observed
TTE min{Ti
*, Ti
C}, i = 1, … which is consistent with the
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number of tumor responses ∑i = 1
N Yi where Yi is the
tumor response indicator of the ith patient (Appendix).
However, deriving the analytical form of the joint distri-
bution of these two statistics by using the copula struc-
ture is not possible. Hence, we used a simulation-based
approach (Appendix section B) to specify the critical
values. The censoring time was generated independently
from an exponential distribution with hazard rate λC to
obtain the observed time because noninformative cen-
soring was assumed in the design. To achieve the prede-
termined censoring rate rC for the TTE, the censoring
hazard rate was set as λC = λrC/(1 − rC), which implies
that the hazard rate λC in generating early stopping rules
for futility (H1) differs from that for activity (H0). For
simplicity, we considered the censoring rates in both H0
and H1 to be the same, although the design allows dis-
tinct censoring for H0 and H1. Because the correlation
coefficient ρ specified in copula (Appendix section A)
influences the decision boundary, the simulation-based
method was adopted under a different correlation setting
to obtain the appropriate decision criterion. We as-
sumed a positive correlation because a high RR is likely
to be associated with a long median TTE regarding TTP
or PFS, when treatment is expected to be active.
In many clinical trials, most investigators prefer to
continue the study to improve the estimation accuracy
at the interim analysis, even if early rejection criteria of
the null hypothesis are fulfilled. Therefore, we consid-
ered only early stopping for futility in the proposed de-
sign. We developed an R computer program for
determining the phase II stopping criteria for the pro-
posed method. Users need to specify the parameters for
the hypotheses, the nominal type I and type II errors,
and a fixed sample size for stage I and the final stage of
the study before we generated a stopping criterion.
Additional file 1: Tables S1a to S1d show the results of
the two-stage stopping rules for the hypotheses, with a
total sample size of 30 and 15 patients used in the first
stage at α = 0.05 and 1 − β = 0.8 at a censoring rate rC =
0.1. The corresponding errors at the early stage (the first
stage) are α1 = 0.01 and β1 = 0.1 according to the error-
spending-function method. In the first example (Add-
itional file 1: Table S1a), a low RR of p0 = 0.05 and a
short median TTE of T0 = 3 were set for the null hy-
pothesis, and p1 = 0.2 and T1 = 4.5 were set for the alter-
native hypothesis. At the first stage with 15 patients,
when the correlation between tumor response and the
underlying true TTE is high (e.g., ρ = 0.8), the null hy-
pothesis would be accepted and the treatment would be
rejected if we observed: (1) no response with a median
TTE of 6.9 or lower; (2) one response with a median
TTE of 4.1 or lower; (3) two responses with a median
TTE of 3.0 or lower; or (4) three responses with amedian TTE of 2.7 or lower. For the final stage, the
treatment would be considered efficacious if we ob-
served: (1) a median TTE of 4.7 or higher with any num-
ber of responses; (2) one response with a median TTE of
4.6 or higher; (3) two or more responses with a median
TTE of 4.5 or higher; (4) three or more responses with a
median TTE of 4.1 or higher; (5) four or more responses
with a median TTE of 3.2 or higher; or (6) five or more
responses with any median TTE.
When implementing the proposed design for a specific
trial, we suggest calculating the correlation based on
RRs and TTEs from historical evidence. For example, if
conducting a phase II trial for assessing bevacizumab ac-
tivity, an angiogenesis inhibitor that slows the growth of
new blood vessels, among patients with hepatocellular
carcinoma (HCC), eight phase II trials on bevacizumab
from 2006 to 2012 could be obtained using PubMed
[22–29]. The results in Table 1 reveal that the Spearman
correlation is estimated to be 0.90, which could be used
as a correlation estimate for the proposed design. If his-
torical results are unavailable, which could be the case
for a relatively new drug, a search method could be ap-
plied to the interim data for estimating the most likely
correlation. We first fixed the correlations and applied
them in the copula setting to calculate the value of the
likelihood function by using the interim data [30]. The
correlation that provides the highest likelihood value
would be an appropriate choice for the design. When in-
terim data are unavailable at the design stage, the deci-
sion rules can be generated under several conditions
(e.g., correlations from 0.1 to 0.9, in 0.1 increments) to
provide a correlation range for reference. We may
choose the maximal number of patients conservatively,
and subsequently apply the likelihood function estima-
tion to determine the most appropriate stopping rules
after interim data are obtained. The calculation program
for either historical results or interim data will be made
available on our website http://www2.ccrb.cuhk.edu.hk.
Results
Simulation study
The simulation study was conducted to evaluate the op-
erating characteristics of the proposed design. For each
scenario, 1,000 samples were generated from the copula
model (Appendix section A) to test the stopping criter-
ion specified by P0, T0, P1, T1 and ρ. With a total of 30
patients and 15 in the early stage, the results in Table 2
(Rows 1–12) indicate that the proposed stopping rules
can generally achieve the desired type I error and
power when high RRs and a high hazard ratio between
null and alternative are expected (P0 = 0.2, T0 = 4, P1 =
0.4 T1 = 8 and P0 = 0.3, T0 = 4, P1 = 0.5 T1 = 8). The type
I error in low RR and low hazard ratio design (P0 =
0.05, T0 = 3, P1 = 0.2 T1 = 4.5) is higher than desired at
Table 1 The tumor response and median PFS of phase II HCC
trials on bevacizumab, 2006-2012












Bevacizumab + Erlotinib 9.0 25
Hsu et al.,
2010 [22]








Bevacizumab + Erlotinib 7.2 23.73
Philip et al.,
2012 [28]
Bevacizumab + Erlotinib 3.0 3.7
Yau et al.,
2012 [29]
Bevacizumab + Erlotinib 1.5 0
Table 2 Simulation results of two-stage design for testing H0:
P ≤ P0 & T
*
med ≤ T0 vs. H1: P > P1 or T
*
med > T1 at the nominal level
α = 0.05 and 1-β = 0.80a
Null Alternative Sample sizeb Corrc
P0 T0 P1 T1 n1 n ρ α 1-β PET
d EN0
e
0.05 3.0 0.20 4.5 15 30 0.8 0.065 0.801 0.786 18.210
0.5 0.065 0.798 0.820 17.700
0.2 0.069 0.801 0.853 17.205
0.0 0.055 0.797 0.893 16.605
0.10 3.0 0.30 5.0 15 30 0.8 0.051 0.794 0.846 17.310
0.5 0.052 0.790 0.884 16.740
0.2 0.038 0.797 0.930 16.050
0.0 0.026 0.791 0.949 15.765
0.20 4.0 0.40 8.0 15 30 0.8 0.046 0.818 0.861 17.085
0.5 0.044 0.800 0.907 16.395
0.2 0.033 0.807 0.945 15.825
0.0 0.021 0.796 0.966 15.510
0.30 4.0 0.50 8.0 15 30 0.8 0.057 0.807 0.841 17.385
0.5 0.037 0.795 0.911 16.355
0.2 0.034 0.796 0.928 16.080
0.0 0.028 0.802 0.950 15.750
0.05 3.0 0.20 4.5 20 40 0.8 0.049 0.807 0.880 22.400
0.5 0.053 0.802 0.892 22.160
0.2 0.044 0.797 0.916 21.680
0.0 0.036 0.804 0.936 21.280
0.10 4.0 0.30 8.0 20 40 0.8 0.053 0.802 0.931 21.380
0.5 0.044 0.806 0.930 21.400
0.2 0.028 0.813 0.957 20.860
0.0 0.025 0.805 0.969 20.620
aThe censoring rates for time-to-event endpoint are set as 0.1 for both
stopping rules and simulated data
bn1 and n denote the sample size in the first stage and the total sample
size, respectively
cρ denotes the correlation between response endpoint and
time-to-event endpoint
dPET denotes the early stopping probability under H0
eEN0 denotes the expected sample size under H0
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when RR increased to P0 = 0.1, P1 = 0.3. When the sam-
ple size increased to n = 40 (the last eight rows in
Table 2), the type I error and power improved to the
acceptable level. In other words, when we expect a low
tumor RR in the study (e.g., cytostatic trial), a sample
size of 40 may be appropriate to achieve the desired
type I error and power. If the expected RR is high
(e.g., chemotherapy in multiple myeloma trials), 30 pa-
tients would be sufficient when using the proposed
phase II design. The early stopping probability and ex-
pected sample size are also affected by a correlation
between tumor response and TTE. The early stopping
probability enhanced when correlation decreased, and
thus less expected sample size was required with lower
correlation between the two endpoints in the trial.
This is reasonable because the more independent the
two endpoints in the study are, the more information
is available for statistical inference.
From the decision rules in Additional file 1: Tables S1a
to S1d, a study agent could be declared to be active with
a sufficiently high RR but with an extremely short me-
dian TTE, or if the median TTE is sufficiently long, but
with a small number of responses. Another situation is if
the treatment has a relatively high median TTE or RR
but is claimed to be inactive, e.g., a trial with no re-
sponse has a median TTE of 6.8 months at the first stage
could be stopped early in the first block of Table S1a,
despite 6.8 months being 2.3 months in excess of what is
defined by the alternative hypothesis. We considered
these clinically ambiguous situations in the simulation
for assessing the performance of the generated decision
rules. The overall type I (an inactive drug incorrectly
claimed as active) and type II errors (an active drugincorrectly claimed as inactive) were still under the de-
sired level (α <0.05, β <0.2), suggesting that the error of
claiming active or inactive drugs with contradictory re-
sults is small.
In generating the decision rules, we employed the ex-
ponential distribution assumption for the TTE out-
come. To assess the sensitivity of the distribution
assumption for the TTE outcome, we performed an-
other simulation where we assumed a more general
Weibull distribution with a diverse shape parameter k.
The Weibull distribution is equivalent to the exponen-
tial distribution when k = 1, implying a constant hazard
during the study. The hazard decreases with time if k
<1 and increases with time if k >1. The results in
Lai and Zee Trials  (2015) 16:250 Page 5 of 10Table 3 indicate that the type I and type II errors in-
crease if the decision rules based on the constant haz-
ard assumption are applied, but they were observed to
decrease. When the magnitude of hazard decrease is
large (k = 0.5) and the total sample size is 40, the type I
and type II errors deteriorate to unacceptable levels (α
>0.1 and power <0.75). The type II error problem can
be rectified by increasing the sample size in the severe
hazard decrease situation (k = 0.5). However, this
strategy has little effect on reducing type I error. When
increased hazard is observed over time, the decisionTable 3 Sensitivity analysis with Weibull distribution assumed
for TTE




P0 T0 P1 T1 ρ n1 n Ka α 1-β PET
0.05 3 0.2 4.5 0.8 20 40 1.0 0.048 0.808 0.891
1.5 0.033 0.855 0.912
1.2 0.036 0.823 0.901
0.8 0.058 0.782 0.863
0.5 0.128 0.719 0.794
0.05 3 0.2 4.5 0.8 30 60 1.0 0.030 0.817 0.958
1.5 0.013 0.871 0.978
1.2 0.028 0.846 0.959
0.8 0.040 0.796 0.930
0.5 0.115 0.782 0.825
0.05 3 0.2 4.5 0.8 40 80 1.0 0.016 0.847 0.977
1.5 0.005 0.888 0.991
1.2 0.008 0.863 0.990
0.8 0.033 0.827 0.955
0.5 0.102 0.818 0.855
0.3 4 0.5 8 0.8 20 40 1 0.047 0.817 0.884
1.5 0.020 0.873 0.949
1.2 0.035 0.834 0.912
0.8 0.062 0.786 0.875
0.5 0.121 0.710 0.793
0.3 4 0.5 8 0.8 30 60 1.0 0.020 0.837 0.965
1.5 0.009 0.881 0.989
1.2 0.014 0.851 0.983
0.8 0.032 0.790 0.949
0.5 0.090 0.742 0.849
0.3 4 0.5 8 0.8 40 80 1.0 0.020 0.857 0.975
1.5 0.005 0.930 0.992
1.2 0.008 0.881 0.990
0.8 0.030 0.833 0.954
0.5 0.096 0.803 0.852
aShape parameter of Weibull distribution assumed for TTE: constant hazard if
K = 1; increase hazard if K >1; decrease hazard if K <1rules lead to fewer type I errors and power. In sum-
mary, only a decreased hazard situation will worsen the
performance of the proposed design based on the expo-
nential distribution assumption for TTE outcome.
We also used the simulation study to compare the
proposed design with the Zee et al. multinomial design,
based on two binary endpoints, as well as with Simon’s
optimal design, based on a single-tumor-response end-
point, with approximately the same sample size and haz-
ard ratio of the event of interest, such as progression.
For example, the scenario with an early progression rate
of 0.6 in H0 and of 0.4 in H1 was considered to have a
hazard ratio of 1.5 in the progression, corresponding to
the situation of T0 = 3 and T1 = 4.5 in Table 2. The re-
sults in Table 4 indicate that the probability of stopping
the study early is similar to the multinomial design and
Simon’s optimal design when tumor RRs for null and al-
ternative hypotheses are P0 = 0.1 versus P1 = 0.3. With
the lower (P0 = 0.05 and P1 = 0.2) or higher tumor RR
(P0 = 0.3 and P1 = 0.5), the proposed design showed
higher early stopping probability compared with both
the multinomial design and Simon’s optimal design.
We also compared the proposed design with those
based on a single TTE endpoint [11, 12]. For example,
we compared a null hypothesis with an RR of 0.1 and a
median TTE of 3 versus an alternative hypothesis with
an RR of 0.3 and a median TTE of 5, using 34 patients
in the first stage and 68 patients in the final stage. The
expected sample size of the approximate survival
method [12] using the TTE alone was 51, with a type I
error equal to 0.097 and a power of 0.850, whereas our
proposed method with mixed RR and TTE endpoints
yields a smaller expected sample size of 34.6, a type I
error of 0.017, and a power of 0.881. For the same hy-
pothesis using 52 patients in the first stage and 81 pa-
tients in the final stage, the expected sample size based
on the TTE endpoint alone [11] was 63.5 with a type I
error of 0.122 and a power of 0.935, and our proposed
method based on mixed RR and TTE endpoints yields a
smaller expected sample size of 52.6 in the presence of a
type I error of 0.019 and a power of 0.979. The results
showed that the mixed-endpoints design has a smaller
expected sample size and higher early stopping probabil-
ity according to H0, indicating that the proposed design
is more likely to stop an inactive agent than those based
on a single TTE endpoint.
Discussion of application
Numerous multistage designs have recently been devel-
oped for phase II clinical trials. However, these designs
are based either on a tumor-response endpoint alone or
a TTE endpoint alone (e.g., progression-free survival).
This, however, may not be the optimal strategy for
evaluating the efficacy of study treatments because a
Table 4 Comparison with Simon’s optimal design and Zee’s multinomial design
P0 T0 P1 T1 ρ
a n1 n Type
b PET α 1-β EN0
0.05 3 0.2 4.5 0.2 21 41 Proposed design 0.855 0.055 0.903 23.900
Simon 0.720 0.046 0.902 26.700
Multinomial 0.770 0.072 0.934 24.600
0.1 3 0.3 5 0.5 10 29 Proposed design 0.788 0.052 0.792 14.028
Simon 0.740 0.047 0.805 15.000
Multinomial 0.655 0.039 0.792 16.900
0.2 4 0.4 8 0.5 13 43 Proposed design 0.874 0.053 0.811 16.780
Simon 0.750 0.049 0.800 20.600
Multinomial 0.723 0.049 0.866 21.300
0.3 4 0.5 8 0.5 15 46 Proposed design 0.880 0.042 0.808 18.720
Simon 0.720 0.049 0.803 23.600
Multinomial 0.763 0.062 0.848 22.100
aCorrelation parameter is set to approximate Zee’s mulatinomial design
bSample size in multinomial design is slightly different (Zee et al., 1999)
cPET and EN0 are obtained from Table III in Whitehead (2014)
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and the TTE [20], and because abandoning either end-
point may cause severe information loss. Although Zee
et al. [16] and Sun et al. [17] proposed multinomial de-
signs to incorporate tumor response and EPD informa-
tion, the dichotomous EPD endpoint does not permit
fully extracting the information from a study, compared
with the TTE endpoint. We generalized these designs to
integrate the tumor response endpoint and the TTE
endpoint, to fully use the information in the study and
to generate efficient stopping rules. We assumed a
Gaussian copula to describe the dependent structure be-
tween binary tumor response and continuous TTE,
which is similar to the binomial-exponential setting used
by de Leon and Wu [30]. Because no analytic solution
exists, we employed a simulation-based method to gen-
erate the stopping rules for tumor response and median
TTE under various fixed correlations between endpoints.
The results of a two-stage design showed that the correl-
ation has an effect on the stopping boundary at the final
stage and on the decision criterion for early stopping in
the first stage. As the correlation decreases, the bound-
ary for early stopping also decreases, meaning that a
shorter median TTE or smaller RR is required to stop
the study at the interim analysis. When we apply the
proposed design in practice, the correlation between RR
and TTE can be estimated from the results of previous
studies. When historical data are unavailable, particularly
for a new drug, the preliminary study data can be used
to estimate the correlation based on the copula likeli-
hood function of the interim data. To make this method
more applicable, we developed an R program for calcu-
lating the correlation.The interim assessment can be planned at the time
when half of the patients achieve progression, or the
time corresponding to each response in the early stop-
ping rules, whichever is shorter. For example, if H0: P
≤0.05 and TTP*med ≤3 versus H1: P >0.2 or TTP
*
med >4.5
and correlation ρ is set as 0.2 to approximate the correl-
ation in the Zee multinomial design, the interim assess-
ments can be conducted at the time when half of the
patients develop progression or 4.5 months, whichever is
shorter, when one response is observed. Compared with
the Zee multinomial design, one advantage of the pro-
posed design is that the interim assessment does not rely
on the progression time and hence we would be able to
decide earlier, which is particularly useful for trials with
long time to progression (e.g., prostate cancer trials).
Compared with those designs based on a single TTE, the
proposed design has the ability to reduce the potential
long waiting time for assessing the TTE outcome if re-
sponse increases.
Similar to the two-stage design based on the TTE end-
point, the proposed design also has the limitation of re-
quiring a longer wait period than tumor response to
obtain the estimated median TTE [14]. However, the
proposed design with the tumor-response endpoint
could mitigate this limitation to a certain extent. For ex-
ample, if a phase II trial is conducted using the sample
size and hypotheses in the last block of Table S1a
(correlation = 0), the clinician must wait 6.6 months or
until the occurrence of eight events (median of 15 pa-
tients), whichever is shorter, when no response is ob-
served at the first stage. If the eighth event occurs before
6.6 months without response, the trial can be stopped
for futility; if less than eight events occur at 6.6 months,
Lai and Zee Trials  (2015) 16:250 Page 7 of 10the study can be continued to stage II. In the event of
one response the waiting period can be reduced to
4.9 months or until eight events have been observed. If
the required period for the TTE endpoint evaluation is
not excessively long in some advanced cancer studies,
the proposed design has the potential to accelerate the
inference, which may improve the efficiency of phase II
clinical trials. Therefore, the introduction of tumor re-
sponse in the proposed design could reduce the poten-
tial waiting time compared with designs based on a
single TTE endpoint.
In our proposed design, we only allow early stopping
for futility, because investigators commonly choose to
continue the study in practice, even if early rejection cri-
teria of the null hypothesis are fulfilled. Considering that
the study would not be stopped early when either of the
endpoints is extremely promising, we used the early re-
jection rules to adaptively bind the early acceptance
rules to obtain reasonable stopping rules for futility.
With 30 patients, the simulation results indicate that the
proposed stopping rules can generally achieve the de-
sired type I error of 5 % and power of 80 % when high
RRs and a high hazard ratio between null and alternative
hypotheses are expected. The type I error in the low RR
and low hazard ratio design is higher than the desired
5 % level. If the sample size increases to 40, the desired
type I and type II errors can be maintained in various
situations. This implies that a sample size of 30 could be
sufficient to achieve the desired type I and type II error
levels for trials with a high expected RR and a high haz-
ard ratio; if a low RR and low hazard ratio are expected,
a slightly larger sample size of 40 may be adequate. If
early stopping for activity is allowed, the boundary of
early rejection may overlap with the boundary of early
acceptance. This means that the conclusion of the effect-
iveness of the study treatment may be contradictory as
being both efficacious and inactive in the first stage, be-
cause of the flexibility (or characteristics) of two diverse
quadrants of parameter space in the response and the
hazard of the TTE. In this case, the adaptive approach
based on early rejection rules may be useful for eliminat-
ing the overlap.
The proposed design assumes that both the response
endpoint and the TTE endpoint indicate study agent ac-
tivity, which may be true in a targeted drug setting with
unknown clinical activity. In the case of a cytostatic
drug, possible tumor shrinkage or response may still in-
dicate drug activity, although inhibited tumor growth is
primarily targeted and the TTE endpoint is commonly
adopted in the assessment. Thus, the null hypothesis can
be rejected and the drug can be accepted if either of
these endpoints exceeds the required level, despite an-
other endpoint indicating futility. Tumor response is
typically positively correlated with the TTE, and anextremely high RR (e.g., >60 %) coinciding with an ex-
tremely small median TTE (e.g., one month) is unlikely.
In the event of this extreme situation occurring, further
investigation of the study agent should be conducted to
determine the mechanism behind the unexpected
observation.
Although exponential distribution is commonly as-
sumed for patient survival [31], the constant hazard im-
plied by exponential distribution may be incorrect in
practical trials. The sensitivity analysis indicated that the
proposed design based on the exponential assumption
for TTE is applicable in practical phase II cancer trials
where the hazard increases with time. However, if the
decreased hazard is observed in the study, the chance of
incorrectly concluding that an inactive drug is active
(type I error) or an active drug is inactive (type II error)
may exceed the expected level. Furthermore, the assess-
ment period, typically scheduled cyclically, may also
affect the estimate of the median TTE [32]. The Pana-
geas’s [32] simulation results showed that the commonly
used upper-limit progression time (where the progres-
sion date is defined as the date at which progression is
first detected during the assessment cycle) could over-
estimate the true median TTP or PFS, thus affecting the
statistical inference only at the final stage rather than at
the early stage. This is because only early acceptance of
null hypotheses is allowed in the proposed design, and
the true median TTE, which is shorter than the esti-
mated TTE, still fulfills the early stopping criteria. Fol-
lowing the recommendation in the Panageas’s study [32],
the upper limit and lower limit (where the progression
date is defined as the date before one cycle at which pro-
gression is first observed) can be combined to draw the
conclusion. The lower limit of the TTE can be employed
to validate the inference based on the commonly used
upper limit of the TTE, when observed results suggest
rejecting the null hypothesis.
We also compared the early stopping probability and
the expected sample size of our design with the Zee
et al. multinomial design based on tumor response and
the binary progression event, as well as with Simon’s op-
timal design based on single tumor response. The simu-
lation results showed that the probability of stopping a
study early is consistently higher, yielding a smaller ex-
pected sample size than Simon’s design, thereby indicat-
ing that integrating the tumor response endpoint and
the TTE endpoint yields more efficient stopping rules
than a design that has only a single tumor-response end-
point. When the expected RR is P0 = 0.1 versus P1 = 0.3,
the performance of the proposed design is approximately
equal to the Zee multinomial design, in early stopping
probability and expected sample size. Unlike in other
scenarios where P0 = 0.05, P1 = 0.2 and P0 = 0.3, P1 = 0.5,
our design has a higher early stopping probability and a
Lai and Zee Trials  (2015) 16:250 Page 8 of 10smaller expected sample size. Therefore, incorporating
TTE into the design exhibits superior performance com-
pared with the Zee design using binary endpoints in the
expected sample size. Furthermore, compared with two-
stage single arm designs based on a single TTE endpoint
[11, 12], the simulation results also indicated the super-
iority of the proposed design in expected sample size
and early stopping probability according to the null
hypothesis.
Conclusions
The proposed single-arm phase II design extends the
Zee multinomial design to fully use the information for
various types of endpoint, where the TTE endpoint
could be progression-free survival. The advantage of this
design is its applicability either to cytotoxic or noncyto-
toxic treatment studies when the median TTE can be
measured in the trials. Our proposed design requires a
smaller expected sample size than other methods for
maintaining the desired statistical properties. Therefore,
when a single-arm design is adopted in a phase II trial
setting, which may be due to limited patient availability
or studies investigating a therapy with only a single
agent [33], it would be a superior choice for drug screen-
ing in phase II clinical trials.
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Additional file 1: Table S1.a Two-stage stopping rules for response and
time-to-event endpointsa with H0: P ≤ 0.05 and T
*
med ≤3 vs. H1: P >0.2 or
T*med >4.5 (α = 0.05, 1-β = 0.80). Table S1.b Two-stage stopping rules for
response and time-to-event endpoints with H0: P ≤0.1 and T
*
med ≤3 vs.
H1: P >0.3 or T
*
med >5 (α = 0.05, 1-β = 0.80). Table S1c Two-stage stopping
rules for response and time-to-event endpoints with H0: P ≤0.2 and T
*
med
≤4 vs. H1: P >0.4 or T
*
med >8 (α = 0.05, 1-β = 0.80). Table S1d Two-stage
stopping rules for response and time-to-event endpoints with H0: P ≤0.3
and T*med ≤4 vs. H1: P >0.5 or T
*
med >8 (α = 0.05, 1-β = 0.80).
Appendix
A. Copula model
Suppose that there are N patients accrued in the study,
for the ith patient we denote the observed binary tumor
response outcome by Yi with value 1 for responders and
value 0 for non-responders, and the underlying true
time-to-event by Ti
* which is assumed to follow an expo-
nential distribution exp (λ). Furthermore, the binary
tumor response is determined by a latent normal vari-
able Xi
* through the probit model
Y i ¼ 0; if X

i ∈ −∞; γð Þ
1; if Xi ∈ γ; þ ∞½ Þ

ðA1Þ
where γ is the unknown threshold that could be deter-
mined by the pre-specified RR in the hypothesis setting.
For example, if the RECIST [34] response rates to axi-
tinib in sorafenib-refractory metastatic renal cellcarcinoma are set as p0 = 0.08 and p1 = 0.2 in Rini et al.
[35], then γ will be 1.41 and 0.84 for null and alternative
hypotheses, respectively. For the unobservable time-to-
event Ti
*, we define the censoring time Ti
C such that Ti
*
could be observed only if Ti
* ≤Ti
C, that is we observe Ti =
min{Ti
*, Ti
C}. Considering the categorical nature of the
tumor response endpoint, we follow de Leon and Wu’s
[30] copula method to model the dependence between
these two endpoints by assuming the correlation between
the underlying normal variable Xi
* and the true time-to-
event Ti
*. One advantage of copula is that it allows one to
easily model the marginal distribution of random vectors
and their correlation separately. Specifically in our design,
the Gaussian copula is used to describe the dependence
between Xi
* and Ti
* once the marginal distributions are as-
sumed, such that the joint distribution is




where Φ is the standard normal distribution represent-
ing the marginal distribution of Xi
*, Φ2 is the standard bi-
variate normal distribution with correlation ρ, and
FT i tð Þ ¼ 1−e−λt is the marginal distribution of true time-
to-event Ti
* with hazard λ. The correlation ρ describes
the dependence between response and the TTE out-
come, which is analogous to the polyserial correlation
defined by Drasgow [36]. Under the Gaussian copula,
the joint distribution of the observed tumor response
outcome Yi and the true time-to-event Ti
* is
P Y i ¼ y;Ti ≤t
  ¼ FXi ;T i γ; tð Þ if y ¼ 0
FTi tð Þ−FXi ;Ti γ; tð Þ if y ¼ 1

ðA3Þ
where FXi ;Ti is defined in (A2).
B. Stopping rule generation procedure for multi-stage
design
For a K-stage design, suppose one decides to accrue ni
patients in the ith stage such that the total number of
patients N = n1 + n2 +… + nK. Let si, i = 1,…, K, denote
the number of patients with response in stage i; and ti
med,




ni observed time-to-event up to the ith
stage. Furthermore, we denote the set of acceptance cri-








Because the early acceptance of study agent is usually
not allowed in practical trials, the decision rules for
rejecting null hypotheses are only applied at the final
stage. Denote the set of rejection criteria of the null hy-
pothesis for response by rY and the rejection criteria for
Lai and Zee Trials  (2015) 16:250 Page 9 of 10time-to-event by rT, a general multi-stage testing proced-
ure is defined as follows. In stage g (g = 1, 2,…, K):














At the final stage, reject H0 and conclude that the
study treatment is efficacious if
Xg
i¼1
si ≥rY or t
med ≥ rT
At the gth stage, the Type I error (αg) and the Type II
error (βg) are adjusted by using the error spending
function in Lan and DeMets [37] and Zee et al. [16] so
that the overall error rates can be controlled at a pre-








, where Z1 − α and Z1 − β
are the (1- α)% quantile and (1- β)% quantile of
standard normal distribution, respectively, and Ng =
n1 + n2 +… + ng. To determine the r
Y , rT, ag
Y, ag
T, for
given αg, βg and corresponding p0, p1, T0, T1 in the
hypothesis setting, the simulation-based approach is
employed:
Step 1. Generate 10,000 samples from the copula (A3)
under the null hypothesis, with a fixed size for the gth





each of the samples.





by using one integer increment for
k and 0.1 unit increment for t.





by using the same increment grid
as in Step 2.
Step 4. Use the copula (A3) to generate another 10,000
samples under the alternative hypothesis for stage g.










 !based on 10,000 samples under the alternative
hypothesis.
Step 6. Determine the decision criterion for the gth
stage based on the distribution tables in step 5. With the
spent error αg and βg, we search the distribution table in
step 5 to find the decision boundary values ag
Y, ag
T for
accepting null hypotheses such that P
Xg
i





Y i≤þ 1; Tmedg ≤þ 0:1
 !
> βg . At the
last stage K, the distribution tables in step 2 and step 3
are searched to find the decision boundary values rY, rT
for rejecting null hypotheses such that P
XK
i










Because two different quadrants are left in the par-
ameter space of response probability and hazard of
TTE, impractical stopping rules may occur as a result,
i.e., design may asks for early termination for futility
when there is zero response with a long median
survival; or a very short median survival with high re-
sponses. However, the drug/treatment is unlikely to be
concluded as inactive if either of the two endpoints
shows promising value (i.e., either high RR or long
median TTE) in practice. To overcome this problem,
the stopping rules for activity, which are generated in
the same way as those in the last stage but with spent
error αg, are proposed to be adaptively bounded by the
rules for futility, so that the cut-off values for early ac-
ceptance of the null hypothesis cannot exceed those
for early rejection. For example, the early acceptance
rules of the null hypothesis could be 1 or less response
with any median TTE, and thus the trial with zero re-
sponse and 7.5 month median TTE at first stage will
be stopped early due to futility. But a long median
TTE could have been inferred as active if the early
stopping rule for activity is median TTE of 6.0 or lon-
ger with any response, indicating that the 7.5 month
median TTE leads us to study the treatment further
rather than stopping early, even though the number of
responses is below the futility boundary. Therefore,
the TTE “tail” of the final early acceptance boundary
is cut off at 1 or fewer response with 6.0 or shorter
median TTE, to avoid the “dilemma” of being con-
cluded as both active and inefficacious. This adaption
is also applied to the response “tail” of the early stop-
ping boundary.
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